Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 126 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Norvasc Clear all

Conditions: Hypertension
Interventions: Aliskiren/Amlodipine, Amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 9
States / cities: Chicago, Illinois • Baltimore, Maryland • Oxon Hill, Maryland + 6 more

Conditions: Hypertension
Interventions: Aliskiren, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Santa Fe, New Mexico

Conditions: Insulin Sensitivity, Aortic Compliance, Diastolic Function
Interventions: Aliskiren, Valsartan and Aliskiren, Amlodipine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions: Amlodipine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Hypertension
Interventions: Placebo, Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule, Amlodipine 10 mg capsule, Aliskiren/amlodipine 150/5 mg tablet, Aliskiren/amlodipine 150/10 mg tablet, Aliskiren/amlodipine 300/5 mg tablet, Aliskiren/amlodipine 300/10 mg tablet; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: PreDiabetes, Impaired Glucose Tolerance, Obesity, Blood Pressure
Interventions: Sacubitril-Valsartan Tab 97-103 MG, Valsartan 160mg, Placebo Oral Tablet; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hypertension
Interventions: Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hypertension
Interventions: QUARTET LDQT, Candesartan; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Bloomingdale, Illinois • Chicago, Illinois

Conditions: Healthy
Interventions: amlodipine 10 mg tablet; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Stage D Heart Failure
Interventions: Sacubitril-Valsartan, Usual care (standard-of-care) arm; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension, Metabolic Syndrome
Interventions: Aliskerin/Valsartan and Rampiril; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypertension
Interventions: Anti-hypertensive agent: amlodipine, Anti-hypertensive agent: Chlorthalidone, Anti-hypertensive agent: Losartan, Home BP monitoring with cuffed device, Home BP monitoring with cuffed device + BP patch, Home BP monitoring with cuffed device + BP watch; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 40 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Primary Aldosteronism, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
Interventions: Amlodipine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension, Genetics Hypertension
Interventions: Eplerenone vs Amlodipine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Amlodipine, Chlorthalidone, Losartan; Drug
Lead sponsor: Anthony J Viera, MD, MPH; Other
Eligibility: 30 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypertension, Coronary Disease, Cerebrovascular Accident
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 55 Years and older
Enrollment: 37,939 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Houston, Texas

Conditions: Hypertension, High Blood Pressure
Interventions: Losartan, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension, Diabetes Type 2
Interventions: Aliskiren, Hydrochlorothiazide; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Hypertension, Mild Cognitive Impairment
Interventions: Candesartan, Lisinopril; Drug
Lead sponsor: Emory University; Other
Eligibility: 55 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pancreatitis
Interventions: amlodipine (drug); Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 72
States / cities: Birmingham, Alabama • Green Valley, Arizona • Mesa, Arizona + 69 more

Conditions: Coarctation of Aorta, High Blood Pressure
Interventions: Losartan, Amlodipine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypertension, Left Ventricular Hypertrophy
Interventions: Eplerenone, Chlorthalidone, Potassium; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance

A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine

Bioequivalency Study of Amlodipine Tablets Under Fasting Conditions

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension

Bioequivalence Study of Amlodipine 10mg Tablets Under Fed Conditions

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

Hypertension in Young Adults Trial

Calcium Channel Blockade in Primary Aldosteronism

Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN

Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study

Analyzing How Genetics May Affect Response to High Blood Pressure Medications

N-of-1 Trials for Blood Pressure Medications in Adults

Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

CAndesartan vs LIsinopril Effects on the BRain

A Pilot Study of Use of Calcium Channel Blocker to Decrease Inflammation and Pain in Hereditary Pancreatitis

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension